^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
lomvastomig (RG7769)
i
Other names: RG7769, RO7121661, RO-7121661, RO 7121661
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
PD1 inhibitor, TIM-3 inhibitor
Related drugs:
10ms
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=210, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
Enrollment closed • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
2years
A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=210, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> May 2025 | Trial primary completion date: Oct 2024 --> May 2025
Trial completion date • Trial primary completion date • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
3years
A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=255, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
Clinical • Enrollment open • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
3years
MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
P1/2, N=735, Recruiting, Hoffmann-La Roche | N=385 --> 735
Clinical • Enrollment change
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (GS-4721) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)
3years
A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus (clinicaltrials.gov)
P2, N=255, Not yet recruiting, Hoffmann-La Roche
Clinical • New P2 trial • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule)
|
CD8 expression • LAG3 expression
|
Opdivo (nivolumab) • lomvastomig (RG7769) • tobemstomig (RG6139)
over3years
MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
P1/2, N=385, Recruiting, Hoffmann-La Roche | Trial completion date: Mar 2023 --> Nov 2024 | Trial primary completion date: Sep 2020 --> Nov 2024
Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (GS-4721) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)
over3years
MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
P1/2, N=385, Recruiting, Hoffmann-La Roche | Trial completion date: Feb 2021 --> Mar 2023
Clinical • Trial completion date • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (GS-4721) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)
almost4years
[VIRTUAL] RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells (AACR-II 2020)
P1 | "RG7769 binds to PD-1 with higher affinity than pembrolizumab and nivolumab. In summary, these preclinical data support the use of RG7769 as a monotherapy and as combination partner for the treatment of patients with solid/hematological tumors. A phase I study is currently ongoing in patients with advanced metastatic solid tumors (NCT03708328)."
Checkpoint inhibition
|
PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • FCGR2A (Fc fragment of IgG receptor IIa)
|
PD-1 expression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • lomvastomig (RG7769)
4years
MORPHEUS mUC: Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) (clinicaltrials.gov)
P1/2, N=305, Recruiting, Hoffmann-La Roche | Trial completion date: Aug 2023 --> Feb 2021
Clinical • Trial completion date • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (GS-4721) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • lomvastomig (RG7769)
Share via
